Wedbush Comments on Global Blood Therapeutics Inc’s Q2 2019 Earnings (NASDAQ:GBT)

Global Blood Therapeutics Inc (NASDAQ:GBT) – Equities research analysts at Wedbush decreased their Q2 2019 earnings per share (EPS) estimates for Global Blood Therapeutics in a research report issued to clients and investors on Tuesday, June 11th. Wedbush analyst L. Moussatos now forecasts that the company will earn ($0.95) per share for the quarter, down from their prior forecast of ($0.05). Wedbush currently has a “Buy” rating and a $107.00 target price on the stock. Wedbush also issued estimates for Global Blood Therapeutics’ Q3 2019 earnings at ($0.97) EPS, Q4 2019 earnings at ($0.99) EPS, FY2019 earnings at ($3.79) EPS, Q1 2020 earnings at ($0.99) EPS, Q2 2020 earnings at ($0.99) EPS, Q3 2020 earnings at ($0.90) EPS, Q4 2020 earnings at ($0.82) EPS, FY2020 earnings at ($3.70) EPS, FY2021 earnings at ($1.96) EPS, FY2022 earnings at $1.27 EPS and FY2023 earnings at $5.59 EPS.

GBT has been the topic of a number of other reports. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $75.00 target price on shares of Global Blood Therapeutics in a research report on Wednesday, May 29th. ValuEngine raised shares of Global Blood Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 1st. BidaskClub downgraded shares of Global Blood Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Oppenheimer upped their target price on shares of Global Blood Therapeutics from $82.00 to $89.00 and gave the stock an “outperform” rating in a research report on Thursday, May 9th. Finally, Guggenheim assumed coverage on shares of Global Blood Therapeutics in a research report on Friday, February 22nd. They issued a “buy” rating and a $75.00 target price on the stock. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $88.29.

NASDAQ:GBT opened at $57.52 on Friday. The company has a quick ratio of 14.51, a current ratio of 14.51 and a debt-to-equity ratio of 0.04. Global Blood Therapeutics has a 1-year low of $30.15 and a 1-year high of $63.00.

Global Blood Therapeutics (NASDAQ:GBT) last released its earnings results on Wednesday, May 8th. The company reported ($0.87) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.94) by $0.07.

A number of institutional investors have recently added to or reduced their stakes in GBT. Truvestments Capital LLC purchased a new stake in Global Blood Therapeutics in the 1st quarter worth approximately $33,000. Kore Private Wealth LLC purchased a new stake in Global Blood Therapeutics in the 1st quarter worth approximately $53,000. Lindbrook Capital LLC purchased a new stake in Global Blood Therapeutics in the 4th quarter worth approximately $55,000. Strs Ohio purchased a new stake in Global Blood Therapeutics in the 4th quarter worth approximately $65,000. Finally, Bank of Montreal Can increased its holdings in Global Blood Therapeutics by 61.9% in the 4th quarter. Bank of Montreal Can now owns 1,582 shares of the company’s stock worth $65,000 after acquiring an additional 605 shares in the last quarter.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Read More: How a Put Option Works

Earnings History and Estimates for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply